Smoking and mental health - NCSCT

Smoking and mental health
31 Health and Social Care in Northern Ireland. Northern Ireland Hospital Statistics: Outpatient
activity statistics 2009/10 (revised). Belfast: Department of Health, Social Services & Public
Safety, 2010.
32 Taylor D, Paton C, Kapur S. The South London and Maudsley & Oxleas NHS Foundation
Trust Prescribing Guidelines, 10th edn. London: Informa Healthcare, 2009.
33 Health and Social Care Information Centre. Prescription Cost Analysis England 2010.
London: Health and Social Care Information Centre, 2011.
34 British National Formulary. Olanzapine, 2012. www.medicinescomplete.com/mc/
bnf/current/PHP18353-olanzapine-non-proprietary.htm#PHP18353-olanzapine-nonproprietary
[Accessed 6 December 2012]
35 Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years’ observations on
male British doctors. British Medical Journal 1994;309:901–11.
36 Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’
observations on male British doctors. British Medical Journal 2004;328:1519.
37 NHS HSCIC. NHS Outcomes Framework indicators – June 2012 Release, 2012.
www.ic.nhs.uk/statistics-and-data-collections/audits-and-performance/nhs-outcomesframework-indicators/nhs-outcomes-framework-indicators—june-2012-release
[Accessed
16 November 2012]
38 McManus S, Meltzer H, Brugha T, et al. Adult psychiatric morbidity in England, 2007. Results of
a household survey. London: The NHS Information Centre for Health and Social Care, 2009.
39 Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and
Northern Ireland – mid 2009. www.ons.gov.uk/ons/publications/re-referencetables.html?edition=tcm%3A77–213645
[Accessed 25 January 2012]
40 American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders,
4th edn (DSM-IV). Washington, DC: American Psychiatric Press, 1994.
41 Drummond M, Sculpher MJ, Torrance GW. Methods for the Economic Evaluation of Health
Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005.
42 Gray A, Clarke P, Wolstenholme J, et al. Applied methods of cost-effectivenesss analysis in
health care. In: Handbooks in Health Economic Evaluation, vol 3. Oxford: Oxford University
Press, 2010.
43 NICE. Guide to the methods of technology appraisal. 2008. www.nice.org.uk.
44 Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice
recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care
Policy and Research. Journal of the American Medical Association 1997;278:1759–66.
45 Parrott S, Godfrey C, Raw M, et al. Guidance for commissioners on the cost effectiveness of
smoking cessation interventions. Health Educational Authority. Thorax 1998;53(suppl 5 Pt
2):S1–38.
46 West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an
update. Health Education Authority. Thorax 2000;55:987–99.
47 Woolacott N, Jones L, Forbes CA, et al. The clinical effectiveness and costeffectiveness of
bupropion and nicotine replacement therapy for smoking cessation: a systematic review
and economic evaluation Health Technology Assessment 2002;6:1–245.
48 Shearer J, Shanahan M. Cost effectiveness analysis of smoking cessation interventions.
Australian and New Zealand Journal of Public Health 2006;30:428–34.
49 National Institute for Health and Clinical Excellence. NICE public health intervention
guidance – Brief interventions and referral for smoking cessation in primary care and other
settings. London: NICE, 2006.
50 Britton J, Edwards R.Tobacco smoking, harm reduction, and nicotine product regulation.
The Lancet 2008;371:441–5.
180 © Royal College of Physicians 2013